Another study found that rIFN-β therapy results in upregulation of both co-stimulatory and regulatory molecules (including PD-L1) on monocytes of MS patients, but upregulation of PD-L2, not of PD-L1, correlated with beneficial outcomes of rIFN-β therapy (70). The gene discussed is PDCD1LG2; the disease is myeloid sarcoma.